tiprankstipranks
Trending News
More News >
Simris Alg AB Class B (SE:SIMRIS.B)
:SIMRIS.B

Simris Alg AB Class B (SIMRIS.B) AI Stock Analysis

Compare
1 Followers

Top Page

SE:SIMRIS.B

Simris Alg AB Class B

(SIMRIS.B)

Select Model
Select Model
Select Model
Neutral 41 (OpenAI - 4o)
Rating:41Neutral
Price Target:
kr0.00
▼(-100.00% Downside)
Simris Alg AB Class B faces significant financial and operational challenges, reflected in its low financial performance score. The technical analysis suggests bearish momentum, with the stock trading below key moving averages and showing oversold conditions. Valuation metrics are unfavorable due to negative earnings and lack of dividends. These factors collectively result in a low overall stock score.
Positive Factors
Sustainable Production
The focus on sustainable production of high-value algae-derived products aligns with growing consumer demand for eco-friendly and health-conscious products, potentially enhancing long-term market positioning.
Strategic Partnerships
Strategic partnerships expand market reach and enhance R&D capabilities, supporting long-term growth and innovation in product offerings.
R&D Capabilities
Strong R&D capabilities through collaborations can lead to innovative product development and maintain competitive advantage in the biotechnology sector.
Negative Factors
Declining Revenues
Significant revenue decline indicates challenges in market demand or competitive positioning, impacting long-term financial health and sustainability.
Negative Cash Flow
Persistent negative cash flow suggests ongoing operational inefficiencies, requiring external financing to sustain operations, which could impact financial stability.
Low Equity Levels
Low equity levels and potential solvency issues raise concerns about the company's ability to withstand financial pressures and invest in growth opportunities.

Simris Alg AB Class B (SIMRIS.B) vs. iShares MSCI Sweden ETF (EWD)

Simris Alg AB Class B Business Overview & Revenue Model

Company DescriptionSimris Alg AB Class B (SIMRIS.B) is a Swedish biotechnology company focused on the sustainable production of high-value products derived from microalgae. Operating primarily in the sectors of food, health, and nutrition, Simris Alg specializes in cultivating various species of algae to create ingredients such as omega-3 fatty acids, proteins, and other bioactive compounds. The company aims to provide natural alternatives to commercially available products, promoting health and wellness while minimizing environmental impact.
How the Company Makes MoneySimris Alg generates revenue primarily through the sale of its algae-derived products, which include omega-3 supplements and other nutritional ingredients. The company has developed a range of branded products aimed at both consumers and health-focused businesses. Key revenue streams include direct sales to consumers via e-commerce platforms, partnerships with health and wellness retailers, and collaborations with food and supplement manufacturers seeking natural ingredients. Additionally, strategic partnerships with research institutions and collaborations with other companies in the biotechnology space enhance its R&D capabilities and market reach, contributing positively to its financial performance.

Simris Alg AB Class B Financial Statement Overview

Summary
Simris Alg AB Class B is facing significant financial challenges, with declining revenues, deepening net losses, and negative cash flows. The company's balance sheet shows vulnerability due to low equity and ongoing liquidity concerns. To ensure long-term viability, the company needs to improve operational efficiency, stabilize revenues, and manage cash flows effectively.
Income Statement
Simris Alg AB Class B has faced declining revenues, evident from a revenue drop from SEK 4.35M in 2023 to SEK 2.89M in 2024. Consistent negative EBIT and EBITDA margins highlight operational inefficiencies, with the EBIT margin at -1201% for 2024. Despite a gross profit margin of 42.11% in 2024, the net profit margin remains deeply negative, reflecting significant net losses. These factors indicate substantial challenges in achieving profitability.
Balance Sheet
The balance sheet reveals a highly leveraged position with a debt-to-equity ratio at zero due to no reported debt, but low equity levels of SEK 5.64M. The equity ratio has drastically decreased to 3.59% in 2024, suggesting potential solvency issues. The return on equity is negative due to persistent net losses, which raises concerns about shareholder value.
Cash Flow
Operating cash flow improved compared to the prior year, though still negative at SEK -18.02M in 2024, indicating ongoing cash burn. The free cash flow remains negative, suggesting unsustainable operations without external financing. Despite this, financing cash flow at SEK 14.91M shows efforts to secure additional funding. The free cash flow to net income ratio remains negative, reflecting challenges in converting income into cash.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.58M2.89M4.35M4.08M6.14M2.17M
Gross Profit1.80M1.22M2.01M-742.00K-2.07M-2.75M
EBITDA-12.86M-17.59M-22.36M-18.00M-24.81M-20.66M
Net Income-29.35M-34.60M-37.30M-24.42M-28.36M-25.60M
Balance Sheet
Total Assets144.79M157.06M174.55M185.71M29.20M57.06M
Cash, Cash Equivalents and Short-Term Investments1.03M1.95M5.67M3.99M961.00K16.51M
Total Debt90.78M2.04M2.67M2.13M3.13M3.99M
Total Liabilities152.53M151.42M148.94M162.68M10.98M9.64M
Stockholders Equity-7.75M5.64M25.61M23.03M18.22M47.42M
Cash Flow
Free Cash Flow-13.32M-18.63M-37.96M-40.57M-18.39M-19.77M
Operating Cash Flow-13.32M-18.02M-36.35M-18.19M-18.14M-19.48M
Investing Cash Flow-613.00K-613.00K-1.61M-22.38M-253.00K-286.00K
Financing Cash Flow13.22M14.91M39.63M43.60M2.84M28.42M

Simris Alg AB Class B Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.04
Price Trends
50DMA
0.09
Negative
100DMA
0.11
Negative
200DMA
0.12
Negative
Market Momentum
MACD
-0.01
Positive
RSI
31.55
Neutral
STOCH
29.21
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SIMRIS.B, the sentiment is Negative. The current price of 0.04 is below the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.09, and below the 200-day MA of 0.12, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 31.55 is Neutral, neither overbought nor oversold. The STOCH value of 29.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SIMRIS.B.

Simris Alg AB Class B Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
kr75.25M-9.14-78.79%20.55%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
43
Neutral
kr82.15M-4.69-601.02%
43
Neutral
kr42.57M-1.52-166.94%-19.35%
42
Neutral
kr12.12M-0.15-213.85%
41
Neutral
kr60.01M-0.93-88.65%8.46%11.73%
41
Neutral
kr28.01M-0.69-49.72%36.20%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:SIMRIS.B
Simris Alg AB Class B
0.04
-0.05
-53.19%
SE:PILA
PILA PHARMA AB
1.81
-2.07
-53.35%
SE:ONCOZ
OncoZenge AB
5.80
1.71
41.98%
SE:LPGO
Lipigon Pharmaceuticals AB
0.02
-0.06
-75.31%
SE:MODTX
Modus Therapeutics Holding AB
0.34
-0.26
-43.31%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
16.96
-6.24
-26.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 19, 2025